Protocol To Evaluate Patient Measurements After Ultrasonic Treatment

Inclusion criteria

• Healthy Female between 20 and 50 years of age, inclusive, on the day of enrolment.
• Has a BMI between 20 and 30 kg/m2.
• Is to be treated in the posterior thigh / saddlebag area using the MC1.
• Has never been treated with the MC1 before.
• Females who are post menopausal or using a medically acceptable form of birth control prior to study enrollment and during the course of the study. (i.e., condoms with spermicide, oral contraceptives contraceptive implants etc.)

Exclusion criteria

• Subject is lactating, has a positive pregnancy test within 7 days of planned study procedure (for female subjects of child-bearing potential), or intends to become pregnant during the study.
• Currently enrolled in another device or drug study that has not completed the required follow-up period, or has completed all other study-required follow-up less than 30 days before enrolment in this study.
• Keloid scars, hypertorphic scars or a history of abnormal healing.
• Any known bruising disorder, anticoagulative / thromboembolic condition , hemorrhagic (bleeding) status or use of anti coagulants.
• Tissue ischemia in the area to be treated.
• Suffering from concurrent conditions such as liver or kidney disorders, Hypertension or abnormally high blood pressure.
• High cholesterol and/or diabetes.
• Active collagen vascular disease (e.g. fibromyalgia, panniculitis, lupus etc.).
• Epilepsy.
• Tuberculosis.
• Auxiliary electric organs (such as pacemakers), metal or myoelectric prosthesis.
• Suffering from Endocrine syndromes or thyroid hyperfunction.
• Active skin infection, any infection in the treated area within the last 30 days or skin disease in the area to be treated (e.g. eczema, psoriasis, urticaria, dermographism).
• Bone, muscle or joint disease, dysfunction or healing in the area to be treated.
• Malignancy in the area to be treated.
• Laminectomy in the area to be treated.